Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grzegorz Kijanka

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Postepy Biochemii|March 6, 2010
[Transformations of erythrocytes shape and its regulation]Maria Stasiuk, Grzegorz Kijanka, Arkadiusz Kozubek
Pharmaceutical Research|January 31, 2013
Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant miceGrzegorz Kijanka, Wim Jiskoot, Huub Schellekens, et al.
Plos One|January 28, 2014
Influence of aggregation and route of injection on the biodistribution of mouse serum albuminGrzegorz Kijanka, Malgorzata Prokopowicz, Huub Schellekens, et al.
Journal of Pharmaceutical Sciences|September 16, 2014
Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4⁺ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvantsGrzegorz Kijanka, Melody Sauerborn, Louis Boon, et al.
Journal of Pharmaceutical Sciences|April 6, 2016
Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in MiceGrzegorz Kijanka, Jared S Bee, Steven M Bishop, et al.
Journal of Pharmaceutical Sciences|March 13, 2014
Development of a transgenic mouse model to study the immunogenicity of recombinant human insulinRiccardo Torosantucci, Vera Brinks, Grzegorz Kijanka, et al.
Journal of Pharmaceutical Sciences|June 4, 2017
Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic ProteinsLora Hamuro, Grzegorz Kijanka, Francis Kinderman, et al.
Journal of Pharmaceutical Sciences|April 29, 2019
Monoclonal Antibody Dimers Induced by Low pH, Heat, or Light Exposure Are Not Immunogenic Upon Subcutaneous Administration in a Mouse ModelGrzegorz Kijanka, Jared S Bee, Mark A Schenerman, et al.
Journal of Pharmaceutical Sciences|July 14, 2018
Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in MiceGrzegorz Kijanka, Jared S Bee, Samuel A Korman, et al.
Journal of Pharmaceutical Sciences|April 6, 2016
Mouse Models for Assessing Protein Immunogenicity: Lessons and ChallengesWim Jiskoot, Grzegorz Kijanka, Theodore W Randolph, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Postepy Biochemii|March 6, 2010
[Transformations of erythrocytes shape and its regulation]Maria Stasiuk, Grzegorz Kijanka, Arkadiusz Kozubek
Pharmaceutical Research|January 31, 2013
Effect of treatment regimen on the immunogenicity of human interferon Beta in immune tolerant miceGrzegorz Kijanka, Wim Jiskoot, Huub Schellekens, et al.
Plos One|January 28, 2014
Influence of aggregation and route of injection on the biodistribution of mouse serum albuminGrzegorz Kijanka, Malgorzata Prokopowicz, Huub Schellekens, et al.
Journal of Pharmaceutical Sciences|September 16, 2014
Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4⁺ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvantsGrzegorz Kijanka, Melody Sauerborn, Louis Boon, et al.
Journal of Pharmaceutical Sciences|April 6, 2016
Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in MiceGrzegorz Kijanka, Jared S Bee, Steven M Bishop, et al.
Journal of Pharmaceutical Sciences|March 13, 2014
Development of a transgenic mouse model to study the immunogenicity of recombinant human insulinRiccardo Torosantucci, Vera Brinks, Grzegorz Kijanka, et al.
Journal of Pharmaceutical Sciences|June 4, 2017
Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic ProteinsLora Hamuro, Grzegorz Kijanka, Francis Kinderman, et al.
Journal of Pharmaceutical Sciences|April 29, 2019
Monoclonal Antibody Dimers Induced by Low pH, Heat, or Light Exposure Are Not Immunogenic Upon Subcutaneous Administration in a Mouse ModelGrzegorz Kijanka, Jared S Bee, Mark A Schenerman, et al.
Journal of Pharmaceutical Sciences|July 14, 2018
Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in MiceGrzegorz Kijanka, Jared S Bee, Samuel A Korman, et al.
Journal of Pharmaceutical Sciences|April 6, 2016
Mouse Models for Assessing Protein Immunogenicity: Lessons and ChallengesWim Jiskoot, Grzegorz Kijanka, Theodore W Randolph, et al.
Pageof 1